SG11201901328VA - Ppar? agonist for treatment of bone disorders - Google Patents
Ppar? agonist for treatment of bone disordersInfo
- Publication number
- SG11201901328VA SG11201901328VA SG11201901328VA SG11201901328VA SG11201901328VA SG 11201901328V A SG11201901328V A SG 11201901328VA SG 11201901328V A SG11201901328V A SG 11201901328VA SG 11201901328V A SG11201901328V A SG 11201901328VA SG 11201901328V A SG11201901328V A SG 11201901328VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- treatment
- bone disorders
- suite
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 iivi HIM 3E1 0 011110 0 100 1110 IMIII0 111110 ill OEN Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/035449 Al 22 February 2018 (22.02.2018) WIP0 I PCT (51) International Patent Classification: A61K 31/7088 (2006.01) Cl 2N 15/113 (2010.01) Published: C07H 21/04 (2006.01) C12Q 1/68 (2006.01) — with international search report (Art. 21(3)) (21) International Application Number: PCT/US2017/047584 (22) International Filing Date: 18 August 2017 (18.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/376,732 18 August 2016 (18.08.2016) US (71) Applicant: INTEKRIN THERAPEUTICS, INC. [US/US]; 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065 (US). (72) Inventor: LANFEAR, Dennis; 80 Valencia Court, Portola Valley, CA 94028 (US). (74) Agent: POLYAKOV, Mark, V. et al.; Wood, Phillips, Katz, Clark & Mortimer, 500 West Madison Street, Suite 1130, Chicago, IL 60661 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 1-1 ON (54) Title: PPARY AGONIST FOR TREATMENT OF BONE DISORDERS 71' 71' (57) : Methods of treatment of bone disorders, including osteoporosis or ir) its symptoms, with PPARY agonists, and in particular, the compound of formula M 0 --.... I t .GI (I) known as INT131 : (I) 1-1 0 ei \"a (I). C
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376732P | 2016-08-18 | 2016-08-18 | |
| PCT/US2017/047584 WO2018035449A1 (en) | 2016-08-18 | 2017-08-18 | Pparϒ agonist for treatment of bone disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901328VA true SG11201901328VA (en) | 2019-03-28 |
Family
ID=61197122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202101500WA SG10202101500WA (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS |
| SG11201901328VA SG11201901328VA (en) | 2016-08-18 | 2017-08-18 | Ppar? agonist for treatment of bone disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202101500WA SG10202101500WA (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190167660A1 (en) |
| EP (1) | EP3500269A4 (en) |
| JP (2) | JP2019524889A (en) |
| KR (1) | KR20190065252A (en) |
| CN (1) | CN109843292A (en) |
| AU (1) | AU2017313842A1 (en) |
| BR (1) | BR112019003133A2 (en) |
| CA (1) | CA3033971A1 (en) |
| EA (1) | EA201990513A1 (en) |
| SG (2) | SG10202101500WA (en) |
| WO (1) | WO2018035449A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| BR112019020485A2 (en) | 2017-04-03 | 2020-05-12 | Coherus Biosciences, Inc. | PPARY AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2407587A1 (en) * | 2000-04-28 | 2001-11-08 | Sankyo Company, Limited | Ppar.gamma. modulators |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| WO2005086904A2 (en) * | 2004-03-08 | 2005-09-22 | Amgen Inc. | Therapeutic modulation of ppar (gamma) activity |
| ES2883141T3 (en) * | 2013-01-30 | 2021-12-07 | Intekrin Therapeutics Inc | PPAR-gamma agonist for the treatment of multiple sclerosis |
| PT3203999T (en) * | 2014-10-10 | 2020-04-23 | Liminal Biosciences Ltd | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis |
-
2017
- 2017-08-18 CA CA3033971A patent/CA3033971A1/en active Pending
- 2017-08-18 CN CN201780063392.8A patent/CN109843292A/en active Pending
- 2017-08-18 US US16/326,070 patent/US20190167660A1/en not_active Abandoned
- 2017-08-18 BR BR112019003133-2A patent/BR112019003133A2/en unknown
- 2017-08-18 SG SG10202101500WA patent/SG10202101500WA/en unknown
- 2017-08-18 KR KR1020197007605A patent/KR20190065252A/en not_active Application Discontinuation
- 2017-08-18 SG SG11201901328VA patent/SG11201901328VA/en unknown
- 2017-08-18 AU AU2017313842A patent/AU2017313842A1/en not_active Abandoned
- 2017-08-18 JP JP2019530368A patent/JP2019524889A/en active Pending
- 2017-08-18 EP EP17842205.1A patent/EP3500269A4/en not_active Withdrawn
- 2017-08-18 WO PCT/US2017/047584 patent/WO2018035449A1/en unknown
- 2017-08-18 EA EA201990513A patent/EA201990513A1/en unknown
-
2022
- 2022-06-03 JP JP2022090843A patent/JP2022116294A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN109843292A (en) | 2019-06-04 |
| AU2017313842A1 (en) | 2019-03-07 |
| US20190167660A1 (en) | 2019-06-06 |
| JP2022116294A (en) | 2022-08-09 |
| SG10202101500WA (en) | 2021-03-30 |
| EP3500269A1 (en) | 2019-06-26 |
| BR112019003133A2 (en) | 2019-05-21 |
| EP3500269A4 (en) | 2020-04-15 |
| EA201990513A1 (en) | 2019-08-30 |
| KR20190065252A (en) | 2019-06-11 |
| CA3033971A1 (en) | 2018-02-22 |
| WO2018035449A1 (en) | 2018-02-22 |
| JP2019524889A (en) | 2019-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
| SG11201906373VA (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201810210UA (en) | Engineered botulinum neurotoxins | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201901320WA (en) | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
| SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201900043TA (en) | Antibody formulations | |
| SG11201804884PA (en) | Method for modulating autophagy and applications thereof | |
| SG11201909107YA (en) | Stenosis treatment |